Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Drug, indicated for the treatment of migraine attacks, are therapeutically equivalent to Imitrex tablets from GlaxoSmithKline
Subscribe to our email newsletter
Caraco Pharmaceutical has launched sumatriptan succinate tablets on behalf of Sun Pharmaceutical Industries, immediately following Sun Pharma’s recently received FDA approval for its Abbreviated New Drug Application (ANDA) for generic Imitrex tablets.
Reportedly, Sumatriptan succinate tablets are indicated for the acute treatment of migraine attacks with or without aura in adults. The tablets, 25mg (base), 50mg (base), and 100mg (base) are therapeutically equivalent to Imitrex tablets from GlaxoSmithKline.
Detroit based Caraco Pharmaceutical Laboratories develops, manufactures, markets and distributes generic and private-label pharmaceuticals to wholesalers, distributors, drugstore chains and managed care providers.